Coppell Advisory Solutions’s Travere Therapeutics TVTX Stock Holding History

Coppell Advisory Solutions’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$452K	Buy	+12,304	New	+$546K	0.04%	304

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Coppell Advisory Solutions's TVTX Position: Q2 2026 in Review

Coppell Advisory Solutions opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 12,304 shares worth $452K. The stake represents 0.04% of the portfolio and ranks #304 among its holdings.

321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Coppell Advisory Solutions held 12,304 shares of Travere Therapeutics worth $452K as of Q2 2026.
Travere Therapeutics was a new Coppell Advisory Solutions position in Q2 2026.
Travere Therapeutics made up 0.04% of Coppell Advisory Solutions's portfolio in Q2 2026, its #304 holding.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Coppell Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.